We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets open in 1 hr 14 mins

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.33 + 0.33 (+0.83%)
At close: 4:02PM EDT
Full screen
Previous Close 40.00
Open 40.17
Bid 40.50 x 300
Ask 40.53 x 1900
Day's Range 40.14 - 40.35
52 Week Range 34.52 - 44.54
Volume 3,387,806
Avg. Volume 3,575,914
Market Cap 99.325B
Beta 0.70
PE Ratio (TTM) 46.14
EPS (TTM) 0.87
Earnings Date Feb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield 2.55 (6.29%)
Ex-Dividend Date N/A
1y Target Est 40.43
Trade prices are not sourced from all markets
  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist 23 hours ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
    Market Realist yesterday

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks 4 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
    Motley Fool 4 days ago

    Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

    Which stock wins in a head-to-head matchup of these two big pharma companies?

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks 5 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • GlobeNewswire 5 days ago

    NeuroMetrix Reports Q1 2018 Financial Results

    WALTHAM, Mass., April 19, 2018-- NeuroMetrix, Inc., today reported financial and business highlights for the quarter ended March 31, 2018.. The Company develops and markets novel therapies, based on neurostimulation ...

  • Reuters 6 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.

  • Business Wire 6 days ago

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Reuters 6 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis, and it showed benefits over other treatments in the study.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters 6 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.